Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies

Project description

A pancreatic cancer nanovaccine

Pancreatic ductal adenocarcinoma is one of the deadliest cancers, with a five-year survival rate below 10 %. It often resists immunotherapy because its dense, immunosuppressive tumour microenvironment restricts effective immune-cell access and function. GlycoIMPACT will investigate aberrantly glycosylated peptides as a promising source of tumour-associated vaccine targets. With the support of the Marie Skłodowska-Curie Actions programme, the GlycoIMPACT project aims to develop liposome-based nanovaccines designed to deliver these tumour targets to immune cells in the skin, triggering immune responses against the tumour. Researchers will use multi-omics data and computational tools to identify the most immunogenic glycopeptide targets. The platform will be validated in pancreatic cancer models, offering a novel precision immunotherapy strategy.

Objective

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a five-year survival rate below 10% due to late diagnosis, immune exclusion, and resistance to existing immunotherapies. GlycoIMPACT tackles these challenges by developing an innovative glycan-based nanovaccine platform targeting tumor-specific glycopeptide neoantigens resulting from abnormal glycoproteomics signatures—markers absent in healthy tissues that enhance immune response specificity. The project has two core objectives. First, it aims to identify and prioritize novel immunogenic PDAC glycopeptides using advanced multi-omics data and computational tools that consider proteomics, glycan features, cellular localization, cancer relevance, and MHC-binding potential. Second, it focuses on engineering and testing targeted liposomal nanovaccines designed for precise delivery to epidermal Langerhans cells via a high-affinity glycomimetic ligand, triggering strong systemic and tissue-resident T-cell responses. The well-studied MUC1-Tn epitope serves as a benchmark to validate new vaccine candidates.
Hosted at the University of Vienna (UNIVIE) with a secondment at the University of La Rioja (UR), the project integrates complementary expertise in nanomedicine, glycoimmunology, peptide synthesis, and computational biology. The researcher benefits from comprehensive training in synthesis, immunological assays, molecular simulations, and nanoparticle engineering, fully aligned with MSCA career development standards. A focused dissemination and exploitation plan supports translation to clinical applications and strengthens European leadership in glycoimmunotherapy.
GlycoIMPACT combines interdisciplinary innovation with translational science, offering a promising strategy to overcome PDAC immunotherapy resistance. It empowers the researcher with advanced skills and lays the groundwork for novel cancer vaccines that could significantly improve patient outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSITAT WIEN
Net EU contribution
€ 230 184,72
Address
UNIVERSITATSRING 1
1010 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)